Why the study?
The study aimed to investigate the clinical features, biochemical, histopathological, and genetic findings in patients diagnosed with the myopathic form of CPT II deficiency.
CPT II deficiency should be considered in the differential diagnosis of recurrent rhabdomyolysis even if typical acylcarnitine elevation is absent, highlighting the importance of genetic analysis.
Answers are grounded in this paper and cite their sources.
Normal acylcarnitine profiles may miss myopathic CPT II deficiency; hypothesis-generating for genetic testing in unexplained rhabdomyolysis.
OBJECTIVES: Carnitine palmitoyltransferase II (CPT II) deficiency is an autosomal recessive disorder of long-chain fatty acid oxidation. Three clinical phenotypes, lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form, have been described in CPT II deficiency. The myopathic form is usually mild and can manifest from infancy to adulthood, characterised by recurrent rhabdomyolysis episodes. The study aimed to investigate the clinical features, biochemical, histopathological, and genetic findings of 13 patients diagnosed with the myopathic form of CPT II deficiency at Ege University Hospital. METHODS: A retrospective study was conducted with 13 patients with the myopathic form of CPT II deficiency. Our study considered demographic data, triggers of recurrent rhabdomyolysis attacks, biochemical metabolic screening, and molecular analysis. RESULTS: Ten patients were examined for rhabdomyolysis of unknown causes. Two patients were diagnosed during family screening, and one was diagnosed during investigations due to increased liver function tests. Acylcarnitine profiles were normal in five patients during rhabdomyolysis. Genetic studies have identified a c.338C>T (p.Ser113Leu) variant homozygous in 10 patients. One patient showed a novel frameshift variant compound heterozygous with c.338C>T (p.Ser113Leu). CONCLUSIONS: gene analysis should be performed. Our study emphasizes that CPT II deficiency should be considered in the differential diagnosis of recurrent rhabdomyolysis, even if typical acylcarnitine elevation does not accompany it.
No takes yet. Share an insight, caveat, or question.
Yazıcı et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: